Tags

Type your tag names separated by a space and hit enter

[Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial].
Arch Mal Coeur Vaiss. 1987 Jun; 80(6):952-5.AM

Abstract

Labetalol was compared with methyldopa in a randomised trial involving 176 pregnant women with mild to moderate hypertension. Effective blood pressure control (diastolic pressure below 86 mmHg) was obtained in a similar proportion of mothers given labetalol or methyldopa, but the addition of a complementary treatment to achieve control was less frequently needed in the labetalol than in the methyldopa group (12/91 vs 22/85 p less than 0.05). Side effects were mild and resulted in discontinuation of the randomised treatment in 1 mother given labetalol. Pregnancy was terminated by intrauterine death in 4 mothers given methyldopa, and one neonate born to a patient allocated to labetalol died at day 1. The average birthweight and the proportion of premature delivery or of small for gestational age newborns were similar in both treatment groups. Heart rate, blood pressure, respiratory rate and blood glucose did not differ between infants born to the mothers of the labetalol and the methyldopa groups, irrespective of gestational age at birth or birthweight. Blood pressure control is more frequently achieved in hypertensive pregnancies with labetalol than with methyldopa as a first line treatment. Labetalol is safe to the fetus and newborn and might offer a better prevention of intrauterine death than methyldopa.

Authors+Show Affiliations

Plouin PF
Service d'Hypertension, Hôpital Broussais, Paris, France.
Bréart G
No affiliation info available
Maillard F
No affiliation info available
Papiernik E
No affiliation info available
Relier JP
No affiliation info available

MeSH

AdultClinical Trials as TopicFemaleHumansHypertensionLabetalolMethyldopaPregnancyPregnancy Complications, CardiovascularPregnancy OutcomeRandom Allocation

Pub Type(s)

Clinical Trial
Comparative Study
English Abstract
Journal Article
Randomized Controlled Trial

Language

fre

PubMed ID

3116996

Citation

Plouin, P F., et al. "[Maternal Effects and Perinatal Safety of Labetalol in the Treatment of Hypertension in Pregnancy. Comparison With Methyldopa in a Randomized Cooperative Trial]." Archives Des Maladies Du Coeur Et Des Vaisseaux, vol. 80, no. 6, 1987, pp. 952-5.
Plouin PF, Bréart G, Maillard F, et al. [Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial]. Arch Mal Coeur Vaiss. 1987;80(6):952-5.
Plouin, P. F., Bréart, G., Maillard, F., Papiernik, E., & Relier, J. P. (1987). [Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial]. Archives Des Maladies Du Coeur Et Des Vaisseaux, 80(6), 952-5.
Plouin PF, et al. [Maternal Effects and Perinatal Safety of Labetalol in the Treatment of Hypertension in Pregnancy. Comparison With Methyldopa in a Randomized Cooperative Trial]. Arch Mal Coeur Vaiss. 1987;80(6):952-5. PubMed PMID: 3116996.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial]. AU - Plouin,P F, AU - Bréart,G, AU - Maillard,F, AU - Papiernik,E, AU - Relier,J P, PY - 1987/6/1/pubmed PY - 1987/6/1/medline PY - 1987/6/1/entrez SP - 952 EP - 5 JF - Archives des maladies du coeur et des vaisseaux JO - Arch Mal Coeur Vaiss VL - 80 IS - 6 N2 - Labetalol was compared with methyldopa in a randomised trial involving 176 pregnant women with mild to moderate hypertension. Effective blood pressure control (diastolic pressure below 86 mmHg) was obtained in a similar proportion of mothers given labetalol or methyldopa, but the addition of a complementary treatment to achieve control was less frequently needed in the labetalol than in the methyldopa group (12/91 vs 22/85 p less than 0.05). Side effects were mild and resulted in discontinuation of the randomised treatment in 1 mother given labetalol. Pregnancy was terminated by intrauterine death in 4 mothers given methyldopa, and one neonate born to a patient allocated to labetalol died at day 1. The average birthweight and the proportion of premature delivery or of small for gestational age newborns were similar in both treatment groups. Heart rate, blood pressure, respiratory rate and blood glucose did not differ between infants born to the mothers of the labetalol and the methyldopa groups, irrespective of gestational age at birth or birthweight. Blood pressure control is more frequently achieved in hypertensive pregnancies with labetalol than with methyldopa as a first line treatment. Labetalol is safe to the fetus and newborn and might offer a better prevention of intrauterine death than methyldopa. SN - 0003-9683 UR - https://www.unboundmedicine.com/medline/citation/3116996/[Maternal_effects_and_perinatal_safety_of_labetalol_in_the_treatment_of_hypertension_in_pregnancy__Comparison_with_methyldopa_in_a_randomized_cooperative_trial]_ DB - PRIME DP - Unbound Medicine ER -